MCID: PSR001
MIFTS: 66

Psoriatic Arthritis

Categories: Genetic diseases, Skin diseases

Aliases & Classifications for Psoriatic Arthritis

MalaCards integrated aliases for Psoriatic Arthritis:

Name: Psoriatic Arthritis 53 12 72 24 71 40 14
Psoriatic Arthritis, Susceptibility to 53 28 13
Psoriatic Arthropathy 12 24 71
Arthropathic Psoriasis 12 24
Arthritis, Psoriatic 41 69
Psoriasis Arthropathica 71
Arthritis Psoriatica 12
Arthritic Psoriasis 71
Arthritis Psoriatic 51
Psoras 71

Classifications:



External Ids:

OMIM 53 607507
Disease Ontology 12 DOID:9008
ICD10 32 L40.5 L40.50
ICD9CM 34 696.0
MeSH 41 D015535
NCIt 46 C61277
UMLS 69 C0003872

Summaries for Psoriatic Arthritis

MedlinePlus : 40 Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. You usually get them on your elbows, knees, scalp, back, face, palms and feet, but they can show up on other parts of your body. Some people with psoriasis have psoriatic arthritis. It causes pain, stiffness, and swelling of the joints. It is often mild, but can sometimes be serious and affect many joints. The joint and skin problems don't always happen at the same time. Your doctor will do a physical exam and imaging tests to diagnose psoriatic arthritis. There is no cure, but medicines can help control inflammation and pain. In rare cases, you might need surgery to repair or replace damaged joints.

MalaCards based summary : Psoriatic Arthritis, also known as psoriatic arthritis, susceptibility to, is related to arthritis and spondyloarthropathy 1, and has symptoms including sciatica, muscle cramp and back pain. An important gene associated with Psoriatic Arthritis is LTA (Lymphotoxin Alpha), and among its related pathways/superpathways are Innate Immune System and PAK Pathway. The drugs Methotrexate and Adalimumab have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and bone, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

OMIM : 53 Psoriasis (177900) is a chronic inflammatory skin disease that may have an autoimmune basis. The disorder has a strong but complex genetic basis, with a concordance rate of 50 to 70% among monozygotic twins. Psoriatic arthritis affects more than 10% of patients with psoriasis and, in most cases, there is an association between the severity of the arthritis and the skin involvement (Gudjonsson et al., 2002). (607507)

UniProtKB/Swiss-Prot : 71 Psoriatic arthritis: An inflammatory, seronegative arthritis associated with psoriasis. It is a heterogeneous disorder ranging from a mild, non-destructive disease to a severe, progressive, erosive arthropathy. Five types of psoriatic arthritis have been defined: asymmetrical oligoarthritis characterized by primary involvement of the small joints of the fingers or toes; asymmetrical arthritis which involves the joints of the extremities; symmetrical polyarthritis characterized by a rheumatoid like pattern that can involve hands, wrists, ankles, and feet; arthritis mutilans, which is a rare but deforming and destructive condition; arthritis of the sacroiliac joints and spine (psoriatic spondylitis).

Genetics Home Reference : 24 Psoriatic arthritis is a condition involving joint inflammation (arthritis) that usually occurs in combination with a skin disorder called psoriasis. Psoriasis is a chronic inflammatory condition characterized by patches of red, irritated skin that are often covered by flaky white scales. People with psoriasis may also have changes in their fingernails and toenails, such as nails that become pitted or ridged, crumble, or separate from the nail beds.

Disease Ontology : 12 A syndrome that occurs in humans with psoriasis who also experience symptoms similar to arthritis.

Wikipedia : 72 Arthritis is a term often used to mean any disorder that affects joints. Symptoms generally include... more...

Related Diseases for Psoriatic Arthritis

Diseases related to Psoriatic Arthritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 319)
# Related Disease Score Top Affiliating Genes
1 arthritis 31.9 IL1B LTA MICA MMP3 NOD2 PTPN22
2 spondyloarthropathy 1 31.8 CRP HLA-B MMP3 NOD2 TNF TNFRSF11B
3 reactive arthritis 30.8 CRP HLA-B TNF
4 spondyloarthropathy 30.6 HLA-B HLA-C MMP3 TNF TNFSF11
5 spondylitis 30.5 CRP HLA-B HLA-C LTA MICA NOD2
6 cholangitis 30.4 CRP HLA-B TNF
7 uveitis 30.3 HLA-B NOD2 TNF
8 sclerosing cholangitis 30.3 HLA-B HLA-C TNF
9 meningitis 30.3 CRP IL1B TNF
10 complex regional pain syndrome 30.3 HLA-B IL1B TNF
11 tonsillitis 30.3 IL1B LTA TNF
12 anterior uveitis 30.2 HLA-B PTPN22 TNF
13 vasculitis 30.2 CRP SELE TNF TNFRSF1B
14 adult-onset still's disease 30.2 CRP IL1B TNF
15 colitis 30.2 IL1B NOD2 S100A12 TNF
16 lyme disease 30.2 CRP IL1B TNF
17 crohn's disease 30.2 CRP IL1B NOD2 TNF TNFRSF1B
18 spondylarthropathy 30.2 LTA TNF
19 juvenile rheumatoid arthritis 30.2 CRP IL1B LTA TNF TNFRSF1B
20 pneumonia 30.1 CRP IL13 IL1B TNF
21 leishmaniasis 30.1 IL13 IL1B TNF
22 rheumatic disease 30.0 CRP HLA-B IL1B TNF TNFRSF11B
23 joint disorders 30.0 IL1B MMP3 TNF TNFSF11
24 arteries, anomalies of 29.9 CRP IL1B SELE TNF
25 visceral leishmaniasis 29.9 CRP IL13 IL1B TNF
26 psoriasis 29.9 CD58 HLA-C IL13 IL1B LTA MICA
27 osteoporosis 29.9 CRP IL1B TNF TNFRSF11B TNFSF11
28 multicentric reticulohistiocytosis 29.8 TNFRSF11B TNFSF11
29 aseptic meningitis 29.8 CD58 IL1B TNF
30 autoimmune disease 29.7 HLA-B IL1B PTPN22 TNF TNFRSF1B
31 pericarditis 29.6 CRP IL1B TNF TNFRSF1A
32 osteoarthritis 29.6 COMP CRP IL1B MMP3 TNF TNFRSF11B
33 arthropathy 29.4 COMP CRP MICA TNF TNFRSF11B TNFSF11
34 familial mediterranean fever 29.4 CRP IL1B NOD2 TNF TNFRSF1A
35 periodontitis 29.2 CRP IL1B MMP3 TNF TNFRSF11B TNFSF11
36 periodontal disease 29.2 CRP IL1B MMP3 TNF TNFRSF11B TNFSF11
37 synovitis 29.2 COMP CRP IL1B MMP3 SELE TNF
38 bone inflammation disease 28.5 COMP CRP IL1B MMP3 PTPN22 TNF
39 systemic lupus erythematosus 28.5 CRP IL1B LTA PTPN22 SELE TNF
40 rheumatoid arthritis 28.3 COMP CRP HLA-B IL1B MMP3 PTPN22
41 psoriatic juvenile idiopathic arthritis 11.4
42 pustulosis of palm and sole 10.8
43 polyposis, gastric 10.6 IL1B TNF
44 psoriasis 1 10.6 HLA-C MICA
45 sympathetic ophthalmia 10.6 HLA-C LTA TNF
46 glaucomatocyclitic crisis 10.6 HLA-B HLA-C
47 hematopoietic stem cell transplantation 10.6 HLA-B HLA-C TNF
48 geographic tongue 10.6 HLA-B HLA-C TNF
49 inflammatory bowel disease 3 10.6 MICA NOD2 TNF
50 systemic onset juvenile idiopathic arthritis 10.6 IL1B TNF

Graphical network of the top 20 diseases related to Psoriatic Arthritis:



Diseases related to Psoriatic Arthritis

Symptoms & Phenotypes for Psoriatic Arthritis

Clinical features from OMIM:

607507

UMLS symptoms related to Psoriatic Arthritis:


sciatica, muscle cramp, back pain

GenomeRNAi Phenotypes related to Psoriatic Arthritis according to GeneCards Suite gene sharing:

25 (show all 31)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-103 10.27 HLA-C HLA-B
2 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.27 MICA
3 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.27 HLA-B HLA-C
4 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.27 HLA-C HLA-B
5 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.27 MICA
6 Increased shRNA abundance (Z-score > 2) GR00366-A-124 10.27 HLA-C
7 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.27 HLA-C
8 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.27 SELE
9 Increased shRNA abundance (Z-score > 2) GR00366-A-156 10.27 HLA-B HLA-C
10 Increased shRNA abundance (Z-score > 2) GR00366-A-162 10.27 HLA-C
11 Increased shRNA abundance (Z-score > 2) GR00366-A-174 10.27 NOD2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.27 NOD2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.27 HLA-B HLA-C
14 Increased shRNA abundance (Z-score > 2) GR00366-A-189 10.27 SELE
15 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.27 MICA HLA-B NOD2 SELE HLA-C
16 Increased shRNA abundance (Z-score > 2) GR00366-A-192 10.27 NOD2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-202 10.27 HLA-C
18 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.27 NOD2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-31 10.27 HLA-B HLA-C
20 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.27 NOD2
21 Increased shRNA abundance (Z-score > 2) GR00366-A-39 10.27 SELE
22 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.27 NOD2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-46 10.27 MICA
24 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.27 HLA-C
25 Increased shRNA abundance (Z-score > 2) GR00366-A-57 10.27 MICA
26 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.27 HLA-B HLA-C
27 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.27 HLA-B HLA-C
28 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.27 MICA
29 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.27 HLA-C
30 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 TNFRSF11B TNFRSF1A TNFRSF1B IL1B LTA NOD2
31 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 TNFRSF11B TNFRSF1A TNFRSF1B IL1B LTA NOD2

MGI Mouse Phenotypes related to Psoriatic Arthritis:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.25 LTA NOD2 PTPN22 SELE TNF TNFRSF11B
2 hematopoietic system MP:0005397 10.22 PTPN22 SELE TNF TNFRSF11B TNFRSF1A TNFRSF1B
3 homeostasis/metabolism MP:0005376 10.21 TNFRSF1A TNFRSF1B TNFSF11 TNIP1 COMP CRP
4 cardiovascular system MP:0005385 10.2 COMP CRP IL1B LTA PTPN22 SELE
5 immune system MP:0005387 10.2 COMP CRP IL13 IL1B LTA MMP3
6 integument MP:0010771 9.86 TNF TNFRSF1A TNFRSF1B TNFSF11 TNIP1 IL13
7 liver/biliary system MP:0005370 9.7 LTA PTPN22 SELE TNF TNFRSF1A TNFRSF1B
8 respiratory system MP:0005388 9.56 IL13 LTA PTPN22 SELE TNF TNFRSF1A
9 skeleton MP:0005390 9.36 COMP IL13 IL1B LTA MMP3 NOD2

Drugs & Therapeutics for Psoriatic Arthritis

Drugs for Psoriatic Arthritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 165)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
2
Adalimumab Approved Phase 4,Phase 3,Phase 2 331731-18-1 16219006
3
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 2 185243-69-0
4
Infliximab Approved Phase 4,Phase 3,Phase 2 170277-31-3
5
Certolizumab pegol Approved Phase 4,Phase 3,Phase 1 428863-50-7
6
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
7
Menthol Approved Phase 4,Phase 3 2216-51-5 16666
8
Apremilast Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 608141-41-9 11561674
9
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 143 6006
10
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
11 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2
12 beta-endorphin Phase 4
13 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
14 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1
15 Adrenocorticotropic Hormone Phase 4
16 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
17 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
18 Vaccines Phase 4,Phase 2
19 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
20 Hormone Antagonists Phase 4,Phase 2,Phase 1
21 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
22 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1
23 Hormones Phase 4,Phase 2,Phase 1
24 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 1
25 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
26 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2,Phase 1
27 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
28 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
29 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
30 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
31 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
32 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1
33 Melanocyte-Stimulating Hormones Phase 4
34 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
35 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
37 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1
38 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
39 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
40 Folate Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
41 Vitamin B9 Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
42
Rifampin Approved Phase 3 13292-46-1 5381226 5458213
43
Azithromycin Approved Phase 3 83905-01-5 53477736 447043 55185
44
Doxycycline Approved, Investigational, Vet_approved Phase 3 564-25-0 54671203
45
Ustekinumab Approved, Investigational Phase 3,Phase 2 815610-63-0
46
Tofacitinib Approved, Investigational Phase 3 477600-75-2
47
Abatacept Approved Phase 3,Phase 2 332348-12-6 10237
48
Dimethyl fumarate Approved, Investigational Phase 3,Phase 2 624-49-7 5271565 637568
49
Entecavir Approved, Investigational Phase 3 142217-69-4 153941
50 Cytochrome P-450 CYP3A Inducers Phase 3

Interventional clinical trials:

(show top 50) (show all 299)

# Name Status NCT ID Phase Drugs
1 Protocol for H.P. Acthar Gel in Moderately to Severely Active Psoriatic Arthritis Unknown status NCT01939132 Phase 4 Open label H.P. Acthar Gel
2 Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Unknown status NCT02132234 Phase 4 Etanercept;Adalimumab;Certolizumab;Infliximab
3 Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Patients With Psoriasis Unknown status NCT01223976 Phase 4
4 Safety and Efficacy of Gardasil in Females With Juvenile Idiopathic Arthritis (JIA)/Seronegative Arthritis Unknown status NCT00573651 Phase 4
5 A Study in Participants With Psoriatic Arthritis Attending Dermatology Clinics Completed NCT02470481 Phase 4
6 Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice Completed NCT01147874 Phase 4
7 HUmira in Psoriatic Arthritis Completed NCT01465438 Phase 4 Adalimumab
8 Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis Completed NCT00245960 Phase 4 etanercept
9 REPArE: Rating Evaluations in Psoriatic Arthritis (PsA) With Etanercept (Enbrel®) Completed NCT00127842 Phase 4 Etanercept
10 Tumor Necrosis Factors (TNF)-α Blockade for Psoriatic Arthritis Completed NCT00432406 Phase 4 Infliximab;Etanercept
11 Enbrel® in Psoriatic Arthritis Completed NCT00111124 Phase 4 Enbrel®
12 National Psoriasis Foundation - Dendritic Cell-Specific Transmembrane Protein (DC-Stamp) Biomarker Study Completed NCT01123265 Phase 4 Methotrexate;Anti-TNF
13 An Observational Study of Infliximab Injection in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Participants Completed NCT00760669 Phase 4 Infliximab; observational study;Methotrexate; observational study
14 The NOR-SWITCH Study Completed NCT02148640 Phase 4 Innovator infliximab;Biosimilar infliximab
15 Study Evaluating Etanercept in Patients With Rheumatoid Arthritis(RA), Juvenile Idiopathic Arthritis (JIA), or Psoriatic Arthritis (PsA) in Spain Completed NCT00195377 Phase 4 Etanercept
16 Evaluation of a Protocol for Dose Reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF Completed NCT01604629 Phase 4 Reduced doses of anti-TNF;Stable doses of anti-TNF
17 TNFalfa Blocking Treatment of Spondylarthropathies Completed NCT00133315 Phase 4 Infliximab;Etanercept;Adalimumab
18 Centocor Microarray Study of Patients Completed NCT00462072 Phase 4 Infliximab
19 Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet Completed NCT00735787 Phase 4
20 Study Evaluating Etanercept for the Treatment of Moderate to Severe Psoriasis Completed NCT00663052 Phase 4 Etanercept;Etanercept
21 A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation Recruiting NCT02814175 Phase 4 methotrexate (MTX)
22 A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis Recruiting NCT03151551 Phase 4 Ixekizumab;Adalimumab
23 Vascular Inflammation in Psoriasis - Apremilast Recruiting NCT03082729 Phase 4 Apremilast
24 Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo Active, not recruiting NCT02798211 Phase 4 Secukinumab;Secukinumab
25 An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis Enrolling by invitation NCT03022617 Phase 4 Apremilast
26 Clinical Impact of Acthar in the Psoriatic Arthritis Patient (CLIPS) Not yet recruiting NCT03419650 Phase 4 ACTHar
27 Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis Not yet recruiting NCT03445845 Phase 4 Secukinumab;TNF blocker
28 Treatment With Apremilast in Patients With Psoriatic Arthritis Withdrawn NCT02558361 Phase 4 Treatment with Apremilast
29 A Study to Assess the Safety and Effectiveness of Golimumab in Filipino Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Withdrawn NCT01692457 Phase 4 No intervention
30 Initial Treatment With Golimumab in Early PsA Unknown status NCT01871649 Phase 3 golimumab;methotrexate
31 Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis Completed NCT01925768 Phase 3 Apremilast 30 mg;Placebo
32 TIght COntrol of Psoriatic Arthritis Completed NCT01106079 Phase 3 Intensive management or Tight control;Standard management - Control group
33 Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis Completed NCT02024646 Phase 3 210 mg brodalumab;140 mg brodalumab;Placebo
34 Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study Completed NCT01877668 Phase 3 Tofacitinib 5 mg BID;Tofacitinib 10 mg BID;Adalimumab;Placebo;Placebo
35 Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors Completed NCT01882439 Phase 3 Tofacitinib;Tofacitinib;Tofacitinib;Tofacitinib
36 Safety and Efficacy Study of Adalimumab in Patients With Active Psoriatic Arthritis (PsA) Completed NCT00235885 Phase 3 adalimumab
37 Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA) Completed NCT01392326 Phase 3 Secukinumab (75 mg);Secukinumab (150 mg);Placebo Comparator
38 Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis Completed NCT01172938 Phase 3 Apremilast 20mg;Apremilast 30mg;Placebo + 20 mg Apremilast;Placebo + 30 mg Apremilast
39 PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis Completed NCT01212757 Phase 3 Apremilast 20mg;Apremilast 30mg;Placebo + 20 mg Apremilast;Placebo + 30 mg Apremilast
40 PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis Completed NCT01212770 Phase 3 Apremilast 20mg;Apremilast 30mg;Placebo
41 Does Etanercept Influence Tweak Modulation of Inflammation During Inflammatory Rheumatisms (Psoriatic Arthritis and Rheumatoid Arthritis)? Completed NCT02164214 Phase 3 etanercept Treatment
42 Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis Completed NCT00195689 Phase 3
43 Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept Completed NCT01901185 Phase 3 Etanercept / Autoinjector A
44 A Study of Ixekizumab in Participants With Active Psoriatic Arthritis Completed NCT01695239 Phase 3 Ixekizumab;Placebo;Adalimumab
45 Double-blind, Randomized, Placebo-controlled Phase 3 Study of Etanercept in the Treatment of Psoriatic Arthritis and Psoriasis Completed NCT00317499 Phase 3 Etanercept
46 A Study of Golimumab in Participants With Active Psoriatic Arthritis Completed NCT02181673 Phase 3 Placebo;Golimumab
47 Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis Completed NCT01087788 Phase 3
48 A Canadian Open-Label Study to Evaluate the Safety and Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriatic Arthritis (PsA) (ACCLAIM) Completed NCT00427362 Phase 3 Adalimumab
49 A Study of the Safety and Effectiveness of Infliximab for the Treatment of Psoriatic Arthritis Completed NCT00051623 Phase 3 Infliximab
50 A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis Completed NCT00265096 Phase 3

Search NIH Clinical Center for Psoriatic Arthritis

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: arthritis, psoriatic

Genetic Tests for Psoriatic Arthritis

Genetic tests related to Psoriatic Arthritis:

# Genetic test Affiliating Genes
1 Psoriatic Arthritis, Susceptibility to 28 LTA NOD2

Anatomical Context for Psoriatic Arthritis

MalaCards organs/tissues related to Psoriatic Arthritis:

38
Skin, Testes, Bone, T Cells, Liver, Endothelial, Placenta

Publications for Psoriatic Arthritis

Articles related to Psoriatic Arthritis:

(show top 50) (show all 1079)
# Title Authors Year
1
Hyperuricemia in Asian psoriatic arthritis patients. ( 29349920 )
2018
2
Evaluation of Self-reported Patient Experiences: Insights from Digital Patient Communities in Psoriatic Arthritis. ( 29449495 )
2018
3
Secukinumab for the maintenance of glucocorticoid-free remission in a patient with giant cell arteritis and psoriatic arthritis. ( 29394408 )
2018
4
Standards of care and quality indicators for multidisciplinary care models for psoriatic arthritis in Spain. ( 29417210 )
2018
5
Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE). ( 29411182 )
2018
6
Spondyloarthritis: Which composite measures to use in psoriatic arthritis? ( 29416138 )
2018
7
Psoriatic arthritis screening by the dermatologist: development and first validation of the "PURE-4 scale". ( 29430720 )
2018
8
A review of ustekinumab in the treatment of psoriatic arthritis. ( 29439608 )
2018
9
Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints. ( 29425183 )
2018
10
Effect of Biologics on Fatigue in Psoriatic Arthritis: A Systematic Literature Review with Meta-analysis. ( 29452303 )
2018
11
Augmented Th17 Differentiation Leads to Cutaneous and Synovio-Entheseal Inflammation in a Novel Model of Psoriatic Arthritis. ( 29439292 )
2018
12
Correction:<i>Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force</i>. ( 29440019 )
2018
13
Pain threshold and temporomandibular function in systemic sclerosis: comparison with psoriatic arthritis. ( 29445986 )
2018
14
Early Psoriatic Arthritis Versus Early Seronegative Rheumatoid Arthritis: Role of Dermoscopy Combined with Ultrasonography for Differential Diagnosis. ( 29449498 )
2018
15
Minimal Disease Activity among Active Psoriatic Arthritis Patients Treated with Secukinumab: 2-year Results from the FUTURE 2 Study. ( 29409133 )
2018
16
Prevalence and incidence of psoriatic arthritis: A systematic review and meta-analysis. ( 29398124 )
2018
17
Underestimation of Risk of Carotid Subclinical Atherosclerosis by Cardiovascular Risk Scores in Patients with Psoriatic Arthritis: How Far Are We from the Truth? ( 29419446 )
2018
18
Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: A Systematic Literature Review. ( 29441473 )
2018
19
Enthesitis: A hallmark of psoriatic arthritis. ( 29429762 )
2018
20
"STATus of STAT3 in Psoriatic Arthritis." ( 29439293 )
2018
21
Small molecule therapy for managing moderate to severe psoriatic arthritis. ( 28891341 )
2017
22
Association between mean platelet volume and disease severity in patients with psoriasis and psoriatic arthritis. ( 28507491 )
2017
23
Real-world validation of the minimal disease activity index in psoriatic arthritis: an analysis from a prospective, observational, biological treatment registry. ( 28855200 )
2017
24
Psychometric properties of the painDETECT questionnaire in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: Rasch analysis and test-retest reliability. ( 28532452 )
2017
25
Achilles enthesitis defined by ultrasound is not associated with clinical enthesitis in patients with psoriatic arthritis. ( 28879054 )
2017
26
Infliximab-Induced Aseptic Meningitis during the Treatment of Psoriatic Arthritis. ( 28611632 )
2017
27
The LIM-Only Protein Four and a Half LIM Domain Protein 2 Attenuates Development of Psoriatic Arthritis by Blocking Adam17-Mediated Tumor Necrosis Factor Release. ( 28823868 )
2017
28
Secular trends in sickness absence among Swedish patients with ankylosing spondylitis and psoriatic arthritis. ( 28879599 )
2017
29
Severe glandular tularemia in a patient treated with anti-tumour necrosis factor for psoriatic arthritis. ( 28450199 )
2017
30
Rapid dactylitis resolution in a patient with psoriatic arthritis after treatment with ustekinumab. ( 28073691 )
2017
31
Improvement in the Axial Symptoms and Magnetic Resonance Imaging Findings With Apremilast in Psoriatic Arthritis. ( 28832380 )
2017
32
Musculoskeletal ultrasonography for psoriatic arthritis and psoriasis patients: a systematic literature review. ( 28521047 )
2017
33
Successful ustekinumab treatment of noninfectious uveitis and concomitant severe psoriatic arthritis and plaque psoriasis. ( 28833973 )
2017
34
Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective. ( 28945143 )
2017
35
The role of IL-17 in the treatment of psoriatic arthritis. ( 28485176 )
2017
36
Evaluation of fatigue and its correlation with quality of life index, anxiety symptoms, depression and activity of disease in patients with psoriatic arthritis. ( 28507445 )
2017
37
Cardiovascular Morbidity in Psoriatic Arthritis: What Is the Effect of Inflammation? ( 28864663 )
2017
38
ERAP1 and ERAP2 Gene Variations Influence the Risk of Psoriatic Arthritis in Romanian Population. ( 28083616 )
2017
39
Recurrent infections in a patient with psoriatic arthritis and hypogammaglobulinemia, treated with conventional and biologic disease-modifying anti-rheumatic drugs-a primary or secondary entity? ( 28488125 )
2017
40
Association between use of disease-modifying antirheumatic drugs and diabetes in patients with ankylosing spondylitis, rheumatoid arthritis, or psoriasis/psoriatic arthritis: a nationwide, population-based cohort study of 84,989 patients. ( 28496328 )
2017
41
A Review of the Use of Secukinumab for Psoriatic Arthritis. ( 28849401 )
2017
42
Radiographic scoring instruments have moderate sensitivity but high specificity for detecting change in axial psoriatic arthritis. ( 28085226 )
2017
43
A review on golimumab in the treatment of psoriatic arthritis. ( 28838285 )
2017
44
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. ( 28473423 )
2017
45
Income disparities in healthcare use remain after controlling for healthcare need: evidence from Swedish register data on psoriasis and psoriatic arthritis. ( 28527093 )
2017
46
Experience and Satisfaction With a Multidisciplinary Care Unit for Patients With Psoriasis and Psoriatic Arthritis. ( 28844687 )
2017
47
A rare coding allele in IFIH1 is protective for psoriatic arthritis. ( 28501801 )
2017
48
Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study. ( 28521824 )
2017
49
Features of some clinical examination parameters in patients with psoriatic arthritis. ( 28511160 )
2017
50
Economic impact of biologic utilization patterns in patients with psoriatic arthritis. ( 28474139 )
2017

Variations for Psoriatic Arthritis

ClinVar genetic disease variations for Psoriatic Arthritis:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 TNF TNF, -308G-A single nucleotide variant risk factor
2 LTA NM_001159740.2(LTA): c.-9-198A> G single nucleotide variant risk factor rs909253 GRCh37 Chromosome 6, 31540313: 31540313

Expression for Psoriatic Arthritis

Search GEO for disease gene expression data for Psoriatic Arthritis.

Pathways for Psoriatic Arthritis

Pathways related to Psoriatic Arthritis according to GeneCards Suite gene sharing:

(show all 44)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.48 CD58 CRP HLA-B HLA-C IL13 IL1B
2
Show member pathways
13.29 IL13 IL1B LTA PTPN22 TNF TNFRSF1A
3
Show member pathways
13.04 HLA-B HLA-C IL13 IL1B LTA MMP3
4
Show member pathways
12.86 HLA-B HLA-C IL13 IL1B LTA MICA
5
Show member pathways
12.79 LTA TNF TNFRSF11B TNFRSF1A TNFRSF1B
6
Show member pathways
12.79 HLA-B HLA-C IL13 IL1B LTA TNF
7
Show member pathways
12.69 IL1B LTA TNF TNFRSF1A TNFRSF1B
8
Show member pathways
12.66 IL1B LTA TNF TNFRSF1A TNFRSF1B
9
Show member pathways
12.58 HLA-B HLA-C MICA TNF TNFRSF1A
10
Show member pathways
12.54 IL1B LTA TNF TNFRSF11B TNFRSF1A TNFRSF1B
11 12.51 IL1B PTPN22 TNF TNFRSF1A TNFRSF1B TNFSF11
12 12.42 HLA-B HLA-C LTA TNF TNFRSF1A
13
Show member pathways
12.32 IL13 IL1B MMP3 TNF
14 12.24 TNF TNFRSF1A TNFRSF1B TNFSF11
15 12.22 IL1B NOD2 TNF TNFRSF1A
16 12.12 CD58 HLA-B HLA-C SELE
17 12.09 IL1B SELE TNF TNFRSF1A
18
Show member pathways
12.05 HLA-B HLA-C IL13 IL1B LTA TNF
19 12.03 IL1B TNF TNFRSF11B TNFRSF1A TNFSF11
20 11.95 IL13 IL1B MMP3 TNF TNFRSF1B
21 11.86 IL1B MMP3 TNF TNFSF11
22 11.85 IL1B LTA TNF TNFRSF1A TNFSF11
23 11.8 IL13 IL1B LTA TNF
24
Show member pathways
11.76 TNF TNFRSF1A TNFRSF1B TNFSF11
25 11.7 TNF TNFRSF1A TNFRSF1B
26 11.65 IL13 IL1B TNF
27
Show member pathways
11.65 LTA TNF TNFRSF11B TNFRSF1A TNFRSF1B TNFSF11
28
Show member pathways
11.63 IL1B MMP3 SELE TNF TNFRSF1A
29 11.6 LTA TNF TNFRSF1A TNFRSF1B
30
Show member pathways
11.55 LTA TNF TNFRSF1A TNFRSF1B
31 11.53 COMP IL1B SELE TNF
32
Show member pathways
11.47 IL1B TNF TNFRSF11B
33 11.46 IL1B TNF TNFRSF11B TNFSF11
34 11.41 IL13 IL1B TNF TNFRSF1A TNFRSF1B
35
Show member pathways
11.38 TNF TNFRSF1A TNFRSF1B
36 11.36 IL1B SELE TNF
37 11.32 TNF TNFRSF1A TNFRSF1B
38 11.31 IL13 IL1B TNF
39 11.28 IL13 IL1B TNF
40 11.26 IL1B LTA MMP3 NOD2 SELE TNF
41 11.21 IL13 IL1B LTA TNF TNFSF11
42 11.15 NOD2 TNF TNFRSF1A
43 10.84 TNFRSF11B TNFSF11
44 10.77 IL13 IL1B

GO Terms for Psoriatic Arthritis

Cellular components related to Psoriatic Arthritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.91 CD58 HLA-B MICA SELE TNF TNFRSF11B
2 extracellular region GO:0005576 9.73 COMP CRP IL13 IL1B LTA MMP3
3 membrane raft GO:0045121 9.71 SELE TNF TNFRSF1A TNFRSF1B
4 cell surface GO:0009986 9.7 CD58 HLA-B HLA-C MICA NOD2 TNF
5 extracellular space GO:0005615 9.4 COMP CRP IL13 IL1B LTA MICA
6 MHC class I protein complex GO:0042612 9.37 HLA-B HLA-C
7 plasma membrane GO:0005886 10.13 CD58 HLA-B HLA-C LTA MICA NOD2

Biological processes related to Psoriatic Arthritis according to GeneCards Suite gene sharing:

(show all 41)
# Name GO ID Score Top Affiliating Genes
1 regulation of cell proliferation GO:0042127 9.97 TNF TNFRSF11B TNFRSF1A TNFRSF1B
2 leukocyte migration GO:0050900 9.96 CD58 IL1B SELE TNF
3 defense response to bacterium GO:0042742 9.91 MICA NOD2 S100A12 TNF TNFRSF1A
4 defense response GO:0006952 9.9 NOD2 TNF TNFRSF1A TNIP1
5 response to nutrient GO:0007584 9.86 LTA NOD2 TNFRSF11B
6 cellular response to mechanical stimulus GO:0071260 9.85 IL13 IL1B TNFRSF1A
7 cellular response to organic cyclic compound GO:0071407 9.85 IL1B NOD2 TNF
8 immune response GO:0006955 9.85 HLA-B HLA-C IL13 IL1B LTA TNF
9 apoptotic signaling pathway GO:0097190 9.84 TNF TNFRSF11B TNFRSF1B
10 positive regulation of inflammatory response GO:0050729 9.82 S100A12 TNFRSF1A TNIP1
11 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.8 TNF TNFRSF1A TNFRSF1B
12 positive regulation of interleukin-6 production GO:0032755 9.8 IL1B NOD2 TNF
13 regulation of inflammatory response GO:0050727 9.8 NOD2 SELE TNF TNIP1
14 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.8 IL1B NOD2 S100A12 TNF TNFSF11
15 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.8 IL1B NOD2 S100A12 TNF TNFRSF1A TNFSF11
16 positive regulation of interferon-gamma production GO:0032729 9.78 IL1B LTA TNF
17 positive regulation of JNK cascade GO:0046330 9.78 IL1B NOD2 TNF TNFSF11
18 lipopolysaccharide-mediated signaling pathway GO:0031663 9.73 IL1B PTPN22 TNF
19 positive regulation of MAP kinase activity GO:0043406 9.73 NOD2 S100A12 TNF TNFSF11
20 tumor necrosis factor-mediated signaling pathway GO:0033209 9.73 LTA TNF TNFRSF11B TNFRSF1A TNFRSF1B TNFSF11
21 positive regulation of interleukin-8 production GO:0032757 9.72 IL1B NOD2 TNF
22 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.68 IL1B TNF
23 positive regulation of ceramide biosynthetic process GO:2000304 9.66 TNF TNFRSF1A
24 negative regulation of lipid storage GO:0010888 9.65 CRP TNF
25 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.65 HLA-B HLA-C
26 positive regulation of chemokine biosynthetic process GO:0045080 9.64 IL1B TNF
27 death-inducing signaling complex assembly GO:0071550 9.64 TNF TNFRSF1A
28 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.63 IL1B TNF TNFRSF1B
29 cellular response to muramyl dipeptide GO:0071225 9.62 NOD2 PTPN22
30 positive regulation of fever generation GO:0031622 9.61 IL1B TNF
31 sequestering of triglyceride GO:0030730 9.59 IL1B TNF
32 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.58 LTA TNF
33 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.58 IL1B TNF
34 positive regulation of protein K63-linked ubiquitination GO:1902523 9.57 NOD2 PTPN22
35 response to lipopolysaccharide GO:0032496 9.56 IL13 IL1B LTA PTPN22 SELE TNFRSF11B
36 regulation of establishment of endothelial barrier GO:1903140 9.54 IL1B TNF TNFRSF1A
37 positive regulation of chronic inflammatory response to antigenic stimulus GO:0002876 9.52 LTA TNF
38 inflammatory response GO:0006954 9.32 CRP IL13 IL1B S100A12 SELE TNF
39 apoptotic process GO:0006915 10.11 COMP IL1B LTA TNFRSF11B TNFRSF1A TNFRSF1B
40 neutrophil degranulation GO:0043312 10.08 CD58 HLA-B HLA-C S100A12 TNFRSF1B
41 regulation of receptor activity GO:0010469 10.01 IL13 IL1B LTA TNF TNFRSF11B TNFSF11

Molecular functions related to Psoriatic Arthritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.93 CD58 COMP CRP HLA-B HLA-C IL13
2 tumor necrosis factor receptor binding GO:0005164 9.43 LTA TNF TNFSF11
3 tumor necrosis factor-activated receptor activity GO:0005031 9.33 TNFRSF11B TNFRSF1A TNFRSF1B
4 cytokine activity GO:0005125 9.1 IL13 IL1B LTA TNF TNFRSF11B TNFSF11

Sources for Psoriatic Arthritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....